Contrive Datum Insights has published "Biosimulation Market Size, Share & Industry Analysis, By Product (Software, Services, In-house Services, Contract Services), Application (Drug Development, Drug Discovery, Others), Delivery model (Subscription Models, Ownership Models), End-use (Pharmaceutical & Biotechnology Companies, CRO, Regulatory Authorities, Academic Research Institutions), Therapeutic area (Oncology, Infectious Diseases, Cardiovascular Diseases, Others), and Regional Forecast, 2026-2034". The study sizes the global biosimulation market biosimulation market at USD 4.05 billion in 2025 and projects growth from USD 4.72 billion in 2026 to USD 14.94 billion by 2034, a compound annual growth rate of 15.5% across the forecast period.
Biosimulation refers to software platforms and modeling services that use mathematical and computational methods, including physiologically based pharmacokinetic and quantitative systems pharmacology models, to predict how a drug candidate behaves in the body before or alongside physical testing. It is delivered either as licensed or subscription software that a company's own scientists run, or as a modeling project performed by a specialist services provider or contract research organization on the client's behalf. Buyers are pharmaceutical and biotechnology companies, contract research organizations, academic research institutions and regulatory authorities that evaluate simulation-supported submissions.
Broadening regulatory acceptance of model-informed drug development
Broadening regulatory acceptance of model-informed drug development is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 15.5% a year, the product lines exposed to it move fastest: Contract Services compounds at 20.27%, taking its share of revenue from 18% to 26% and its value from USD 0.729 billion to USD 3.884 billion.
On the upside, the study's bull case assumes regulatory agencies broaden model-informed drug development acceptance faster than the base case and enterprise buyers convert to subscription licensing more quickly, lifting seat and service volume growth across every end-use category, which would take 2034 revenue to USD 17.93 billion rather than the USD 14.94 billion base case.
However, regulatory acceptance broadens more slowly than the base case and pharmaceutical and biotechnology buyers delay budget approval for new licenses and outsourced modeling engagements, holding volume growth well below the base case, which would hold 2034 revenue to USD 12.25 billion. Software, which carries 46% of 2025 revenue, already grows at only 14.31% against the market's 15.5%, so the largest part of the base is also its slowest.
Key Players Compete on Software Volume and Contract Services Growth
Competition in the global biosimulation market biosimulation market runs along the product axis rather than the regional one. Software holds 46% of 2025 revenue at USD 1.863 billion and remains the largest line through 2034 at 42%, making it the position hardest for a challenger to take. Contract Services, growing at 20.27%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 4.05 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product | Software | 46% · USD 1.863 billion | — |
| Application | Drug Development | 58% · USD 2.349 billion | Drug Discovery 17.13% |
| Delivery model | Subscription Models | 55% · USD 2.228 billion | — |
| End-use | Pharmaceutical & Biotechnology Companies | 62% · USD 2.511 billion | CRO 17.77% |
| Therapeutic area | Oncology | 34% · USD 1.377 billion | — |
- Based on regional analysis, North America led the global biosimulation market biosimulation market in 2025 with 42% of global revenue at USD 1.701 billion, reaching USD 5.677 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 22% in 2025 to 27% in 2034, with revenue growing from USD 0.891 billion to USD 4.034 billion.
- Middle East and Africa remains the smallest region throughout, at 4% of 2025 revenue and 5% by 2034.
- Contract Services is projected to grow at 20.27% over the forecast period, the fastest of any product line.
- The United States is the largest single country market at USD 1.446 billion in 2025, 35.7% of global revenue.
The report segments the market across five axes; by product, and by application, delivery model, end-use and therapeutic area; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 12.25 billion and USD 17.93 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.